# Use and Impact of Novel and Repurposed Therapeutics for Alzheimer's Disease and Related Dementia in Diverse Populations

> **NIH NIH R61** · UNIVERSITY OF SOUTHERN CALIFORNIA · 2024 · $312,880

## Abstract

Project Summary
The accelerating development of novel AD/ADRD therapeutics and efforts to repurpose
commonly prescribed drugs for other chronic conditions foreshadows future opportunities to
reduce AD/ADRD risk and burden. However, the demand for and access to AD/ADRD
therapeutics is uncertain in underserved non-Hispanic Black communities who are at elevated
AD/ADRD risk and face barriers to use that are particularly acute due to factors such as structural
racism and medical system distrust. Members of non-Hispanic Black communities remain under-
included in AD/ADRD research and the limited evidence available demonstrates that non-
Hispanic Black older adults are diagnosed with AD/ADRD later than non-Hispanic White
Americans and are less likely to receive follow-up care, specialist care and available therapeutics
after an AD/ADRD diagnosis. One strategy to facilitate equitable uptake of future AD/ADRD
therapies is to identify and quantify the demand for and access barriers to potential dementia
treatments from non-Hispanic Black stakeholders’ perspectives and actual use of novel therapies
for non-AD/ADRD conditions. In the planning stage, we will engage non-Hispanic Black
stakeholders and employ NIA’s Health Disparities Framework to guide use of qualitive and
quantitative methods to identify and elicit measurement of key factors related to access and
demand for novel and repurposed therapeutics. In the implementation stage, we will collect and
analyze data from study participants and nationally representative data sources. We will quantify
likelihood of drug initiation, adherence, and discontinuation among non-Hispanic Blacks across
therapeutics with varying cost, efficacy, administration, and side-effect profiles. We will employ
the measures using a validated dynamic microsimulation model to quantify the downstream
impact of novel and repurposed therapeutics on health care costs and the cognitive and physical
health and quality of life of non-Hispanic Black men and women. Findings will inform targeted
opportunities for ensuring equitable access to therapeutics that reduce disease risk and burden
in non-Hispanic Black communities and will quantify the health and economic impacts of
therapeutics to inform public spending and drug innovation efforts for improving health outcomes
and achieving equity.

## Key facts

- **NIH application ID:** 10814331
- **Project number:** 5R61AG081811-02
- **Recipient organization:** UNIVERSITY OF SOUTHERN CALIFORNIA
- **Principal Investigator:** DAVID ALAN BENNETT
- **Activity code:** R61 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $312,880
- **Award type:** 5
- **Project period:** 2023-04-01 → 2025-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10814331

## Citation

> US National Institutes of Health, RePORTER application 10814331, Use and Impact of Novel and Repurposed Therapeutics for Alzheimer's Disease and Related Dementia in Diverse Populations (5R61AG081811-02). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/10814331. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*